Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
Authors
Teresa Macarulla
Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain
Teresa Macarulla , Noboru Yamamoto , Anthony W. Tolcher , Navid Hafez , Iwona Lugowska , Rodryg Ramlau , Junxian Geng , Jian Li , Michael Teufel , Angela Maerten , Patricia LoRusso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03449381 and NCT03964233
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 487)
DOI
10.1200/JCO.2024.42.3_suppl.487
Abstract #
487
Poster Bd #
C12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
First Author: Noboru Yamamoto
Poster
2017 Gastrointestinal Cancers Symposium
Association of UGT1A1 gene polymorphism with the safety and efficacy of irinotecan monotherapy for advanced gastric cancer.
First Author: Toshifumi Yamaguchi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan
Poster
2023 ASCO Annual Meeting
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.
First Author: Ye Guo